Development and biocompatibility assessments of poly(3-hydroxybutyrate-co-ε-caprolactone) microparticles for diclofenac sodium delivery

Osteoarthritis (OA) is a debilitating disease affecting joints and impairing the ability to perform everyday tasks. Current treatment regimens tend to provide little to no relief. Therefore, there is a huge need for alternative strategies to manage this painful condition. The delivery of anti-inflammatory drugs into an injured joint with the aim of eliminating articular inflammation and modulate cartilage damage could be a useful strategy to treat OA. Accordingly, the aim of this study is to prepare microparticles (MPs) from new biodegradable poly (3-hydroxybutyrate-co-ε-caprolactone) copolymers (PHBCL) for the potential intra-articular injection of Diclofenac sodium for OA treatment. MPs were prepared starting from copolymers having different molecular weights and an HB/CL molar ratio and studied for their morphologies and size distribution by scanning electron microscopy. Drug loading and encapsulation efficiency were also determined. The in vitro release profile was assessed by the dialysis bag technique and the kinetic profile was evaluated by using several mathematical models revealing a diffusion release mechanism. A1 polymer and related MPs, as representative of the group, were selected for further biological investigation. In vitro studies performed on CaCo-2 and Balb/3T3 cells showed no toxic effects at the desired concentrations as revealed by MTT, CFE and Comet assays.